社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
fann
IP属地：未知
+关注
帖子 · 45
帖子 · 45
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
fann
fann
·
2021-11-28
v
非常抱歉，此主贴已删除
看
3,946
回复
评论
点赞
2
编组 21备份 2
分享
举报
fann
fann
·
2021-11-24
yes
XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘上涨近12%</blockquote>
XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported
XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘上涨近12%</blockquote>
看
2,604
回复
评论
点赞
5
编组 21备份 2
分享
举报
fann
fann
·
2021-11-13
d
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示出其研发实力雄厚。这对该股来说是个好兆头。</blockquote>
Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo
Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示出其研发实力雄厚。这对该股来说是个好兆头。</blockquote>
看
2,884
回复
评论
点赞
5
编组 21备份 2
分享
举报
fann
fann
·
2021-11-10
h
非常抱歉，此主贴已删除
看
2,965
回复
评论
点赞
4
编组 21备份 2
分享
举报
fann
fann
·
2021-09-26
ss
Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始在亚利桑那州建设两家计算机芯片工厂</blockquote>
Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to
Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始在亚利桑那州建设两家计算机芯片工厂</blockquote>
看
2,230
回复
1
点赞
6
编组 21备份 2
分享
举报
fann
fann
·
2021-09-24
s
EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据，欧盟将等待决定辉瑞加强剂</blockquote>
In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing
EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据，欧盟将等待决定辉瑞加强剂</blockquote>
看
4,688
回复
评论
点赞
5
编组 21备份 2
分享
举报
fann
fann
·
2021-09-21
h
Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>全球股市反弹，道琼斯、纳斯达克、标普500期货上涨</blockquote>
The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again t
Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>全球股市反弹，道琼斯、纳斯达克、标普500期货上涨</blockquote>
看
2,167
回复
2
点赞
3
编组 21备份 2
分享
举报
fann
fann
·
2021-09-21
d
非常抱歉，此主贴已删除
看
3,855
回复
1
点赞
2
编组 21备份 2
分享
举报
fann
fann
·
2021-09-16
b
非常抱歉，此主贴已删除
看
3,515
回复
评论
点赞
1
编组 21备份 2
分享
举报
fann
fann
·
2021-09-13
f
非常抱歉，此主贴已删除
看
3,579
回复
1
点赞
4
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3585997214465926","uuid":"3585997214465926","gmtCreate":1622903189881,"gmtModify":1627956052914,"name":"fann","pinyin":"fann","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":12,"headSize":113,"tweetSize":45,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":600939962,"gmtCreate":1638029748530,"gmtModify":1638029748620,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"v","listText":"v","text":"v","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/600939962","repostId":"2186389343","repostType":4,"isVote":1,"tweetType":1,"viewCount":3946,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":875729976,"gmtCreate":1637697368889,"gmtModify":1637697369016,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"yes","listText":"yes","text":"yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/875729976","repostId":"1117658681","repostType":4,"repost":{"id":"1117658681","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1637681053,"share":"https://www.laohunote.com/m/news/1117658681?lang=zh_CN&edition=full","pubTime":"2021-11-23 23:24","market":"us","language":"en","title":"XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘上涨近12%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1117658681","media":"Tiger Newspress","summary":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported ","content":"<p>XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p><p><blockquote>这家总部位于中国的电动汽车制造商小鹏汽车公布第三季度亏损超出预期，但收入增长远高于预期，并提供了乐观的第四季度前景，该公司股价在早盘交易中上涨近 12%。净亏损从一年前的人民币 11.5 亿元扩大至人民币 15.9 亿元（2.497 亿美元），即每股美国存托股 (ADS) 亏损人民币 1.89 元。不包括非经常性项目，调整后的每股美国存托凭证亏损为人民币 1.77 元，而 FactSet 共识为人民币 1.30 元。</blockquote></p><p> Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p><p><blockquote>收入增长 187.4%，达到人民币 57.2 亿元（8.955 亿美元），超过 FactSet 预期的人民币 50.3 亿元，交付量增长 199.2%，达到创纪录的 25,666 辆，其中 P7 车型交付量增长 217.7%。</blockquote></p><p> Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p><p><blockquote>毛利率从4.6%提高到14.4%。展望未来，该公司预计第四季度交付量将在 34,500 至 36,500 辆之间，增长 166.1% 至 181.5%，收入将在人民币 71 亿元至人民币 75 亿元之间，而 FactSet 共识为人民币 60.9 亿元。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>XPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘上涨近12%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXPeng shares rose nearly 12% in early trading<blockquote>小鹏汽车股价早盘上涨近12%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-23 23:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.<img src=\"https://static.tigerbbs.com/a8d43127b29dfc54fadaa9e23939d911\" tg-width=\"878\" tg-height=\"596\" referrerpolicy=\"no-referrer\">The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.</p><p><blockquote>这家总部位于中国的电动汽车制造商小鹏汽车公布第三季度亏损超出预期，但收入增长远高于预期，并提供了乐观的第四季度前景，该公司股价在早盘交易中上涨近 12%。净亏损从一年前的人民币 11.5 亿元扩大至人民币 15.9 亿元（2.497 亿美元），即每股美国存托股 (ADS) 亏损人民币 1.89 元。不包括非经常性项目，调整后的每股美国存托凭证亏损为人民币 1.77 元，而 FactSet 共识为人民币 1.30 元。</blockquote></p><p> Revenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.</p><p><blockquote>收入增长 187.4%，达到人民币 57.2 亿元（8.955 亿美元），超过 FactSet 预期的人民币 50.3 亿元，交付量增长 199.2%，达到创纪录的 25,666 辆，其中 P7 车型交付量增长 217.7%。</blockquote></p><p> Gross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.</p><p><blockquote>毛利率从4.6%提高到14.4%。展望未来，该公司预计第四季度交付量将在 34,500 至 36,500 辆之间，增长 166.1% 至 181.5%，收入将在人民币 71 亿元至人民币 75 亿元之间，而 FactSet 共识为人民币 60.9 亿元。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"XPEV":"小鹏集团","09868":"小鹏集团-W"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117658681","content_text":"XPeng shares rose nearly 12% in early trading after the China-based electric vehicle maker reported a wider-than-expected third-quarter loss but revenue that rose well above forecasts and provided an upbeat fourth-quarter outlook.The net loss widened to RMB1.59 bln ($249.7 million), or RMB1.89 per American depositary share (ADS), from a loss of RMB1.15 billion a year ago. Excluding nonrecurring items, the adjusted loss per ADS came to RMB1.77, compared with the FactSet consensus of RMB1.30.\nRevenue jumps 187.4% to RMB5.72 billion ($895.5 million) to beat the FactSet consensus of RMB5.03 billion, as deliveries rose 199.2% to a record 25,666 vehicles, including 217.7% growth in P7 model deliveries.\nGross margin improved to 14.4% from 4.6%. Looking ahead, the company expects fourth-quarter deliveries of between 34,500 and 36,500 vehicles, representing growth of 166.1% to 181.5%, and revenue between RMB7.1 billion and RMB7.5 billion, compared with the FactSet consensus of RMB6.09 billion.","news_type":1,"symbols_score_info":{"09868":0.9,"XPEV":0.9}},"isVote":1,"tweetType":1,"viewCount":2604,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":873030150,"gmtCreate":1636789657540,"gmtModify":1636789657680,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/873030150","repostId":"1102251183","repostType":4,"repost":{"id":"1102251183","kind":"news","pubTimestamp":1636772424,"share":"https://www.laohunote.com/m/news/1102251183?lang=zh_CN&edition=full","pubTime":"2021-11-13 11:00","market":"us","language":"en","title":"Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示出其研发实力雄厚。这对该股来说是个好兆头。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1102251183","media":"Barrons","summary":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Mo","content":"<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一清晨，通过电话联系到辉瑞公司的首席科学官米凯尔-多尔斯滕（Mikael Dolsten）时，他听起来头晕目眩。就在几天前，他的公司宣布其 Covid-19 抗病毒药物已将高危成年人的住院风险降低了 89%，这一消息震惊了市场。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>“多尔斯滕说：”这不可能是一件偶然的事情，你能够打破这种世界纪录，同时获得大满贯。他在试图说明辉瑞公司双赢的重要性时，用了体育比喻： 仅用了 10 个月就研制出了一种非常有效的 Covid-19 疫苗，一年后又研制出了一种同样令人惊叹的 Covid-19 抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉 (Albert Bourla) 要求投资者在多尔斯滕十多年来重建的研发业务上下大注。这个赌注看起来比以往任何时候都聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla 已经摆脱了辉瑞公司的非专利药物部门及其最后的消费者保健产品，留下了一家纯粹的生物制药公司，该公司将依靠多尔斯滕的科学力量生死存亡。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在 2019 年 11 月的封面故事中，<i>巴伦</i>认为Bourla和Dolsten能成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞公司的观点：<i>巴伦</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从疫情中获利会带来新的风险。低收入国家在全球70多亿剂疫苗中所占比例不到1%。如果辉瑞公司抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天，辉瑞公司股价飙升 10.9%，创下至少 20 年来最佳单日表现。尽管如此，随着该股目前在 50 美元左右易手，投资者继续低估该公司的估值。投资者对辉瑞公司的定价是明年预期收益的 12 倍，低于强生公司（JNJ）和礼来公司（LLY）等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临的专利悬崖的担忧。该公司将失去少数几种每年带来数十亿美元收入的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这种担忧是合理的，但辉瑞公司的科学政变应该让投资者相信，该公司的科学能够安全地渡过悬崖。市场可能需要时间才能迎头赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞公司科学实力的最好例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>辉瑞公司的 Covid-19 疫苗来自德国生物技术公司 BioNTech (BNTX) 的实验室，而新型 Covid-19 抗病毒药物则是由多尔斯滕所说的辉瑞公司位于美国东北部的实验室科学家 “梦之队 ”研发出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将精力分散在与 BioNTech 在疫苗方面的合作和对 Covid-19 药丸的追求上。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的 “巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目是一个规模小得多的项目——一组辉瑞专家利用疫苗推广剩余的资源开展工作。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“多尔斯滕说：”小分子更像是一个灵活、专注于激光的高端团队，资源相当适中。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括辉瑞公司的药物设计主管夏洛特-阿勒顿（Charlotte Allerton）。科学家们从辉瑞公司几年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“辉瑞的药物研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂是静脉注射给药的，口服给药时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“多尔斯滕说：”他们必须真正创造很多新的化学反应。科学家们创造了 600 种化合物来确定合适的药物，这一过程通常可能需要数年时间，但他们在几个月内就完成了。“他说：”四年在这里变成了四个月。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药丸。目前，该公司正在对该药物进行多项 2/3 期试验，包括一项针对高危患者的试验、一项针对非高危患者的试验以及一项针对接触过病毒但尚未患病的患者的预防措施。在第一次读数中，该药物看起来比默克公司 (MRK) 的 Covid 治疗药丸更有效。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>“Cantor Fitzgerald 的分析师 Louise Chen 说：”这无疑有助于证明（辉瑞的）药品研发比人们想象的要好。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈说，在 Covid-19 疫苗和药丸销售的耐久性得到更明确以及其余的管道得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“她说：”我认为没有一个事件会引发该股的评级被重新评级到下一个级别。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得押注辉瑞成为一项长期战略。与此同时，Moderna (MRNA) 最近几周的经历凸显了疫苗制造商因疫苗分配不均而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对 Moderna 公司越来越不满，呼吁该公司提高产量，以便以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司 “加大力度”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna 股价在过去三个月中下跌了 40% 以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞公司可能会侵蚀大约一年前推出 Covid-19 疫苗时获得的巨大商誉。本月早些时候，辉瑞公司首席执行官布尔拉将疫苗分配不公归咎于低收入国家，并表示<i>巴伦</i>不下单是他们的错。辉瑞公司以非营利价格向美国出售了10亿剂疫苗，用于捐赠给贫困国家，并表示到明年年底将总共至少向中低收入国家交付20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>当谈到抗病毒药物时，辉瑞只表示将为较贫穷的国家提供分层定价，这与它对疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫困国家提供自己的 Covid-19 药丸的计划形成了鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，该协议将允许其药丸在全球获得许可，而默克公司无需支付版税。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕说，辉瑞公司正在考虑按照与默克公司类似的机制对其药片进行许可。“他说：”我们将研究这些方案。“我们绝不是说我们会做一些不同的事情。我们只是想确保无论谁参与其中，都能获得建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的举措来得还不够快。上月底，活动人士在布尔拉家门外举行抗议活动，呼吁辉瑞公司分享其疫苗生产技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞保持相对良好的华盛顿青睐，并使其令人印象深刻的科学继续推高股价。</blockquote></p><p></p>","source":"lsy1601382232898","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示出其研发实力雄厚。这对该股来说是个好兆头。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Shows Its R&D Is Strong. It’s a Good Sign for the Stock.<blockquote>辉瑞显示出其研发实力雄厚。这对该股来说是个好兆头。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Barrons</strong><span class=\"h-time small\">2021-11-13 11:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.</p><p><blockquote>周一清晨，通过电话联系到辉瑞公司的首席科学官米凯尔-多尔斯滕（Mikael Dolsten）时，他听起来头晕目眩。就在几天前，他的公司宣布其 Covid-19 抗病毒药物已将高危成年人的住院风险降低了 89%，这一消息震惊了市场。</blockquote></p><p> “It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.</p><p><blockquote>“多尔斯滕说：”这不可能是一件偶然的事情，你能够打破这种世界纪录，同时获得大满贯。他在试图说明辉瑞公司双赢的重要性时，用了体育比喻： 仅用了 10 个月就研制出了一种非常有效的 Covid-19 疫苗，一年后又研制出了一种同样令人惊叹的 Covid-19 抗病毒药物。</blockquote></p><p> Two years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.</p><p><blockquote>两年前，辉瑞（股票代码：PFE）首席执行官阿尔伯特·布尔拉 (Albert Bourla) 要求投资者在多尔斯滕十多年来重建的研发业务上下大注。这个赌注看起来比以往任何时候都聪明。</blockquote></p><p> Bourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.</p><p><blockquote>Bourla 已经摆脱了辉瑞公司的非专利药物部门及其最后的消费者保健产品，留下了一家纯粹的生物制药公司，该公司将依靠多尔斯滕的科学力量生死存亡。</blockquote></p><p> In a cover story in November 2019, <i>Barron’s</i> argued that Bourla and Dolsten could pull it off.</p><p><blockquote>在 2019 年 11 月的封面故事中，<i>巴伦</i>认为Bourla和Dolsten能成功。</blockquote></p><p> The new antiviral data reaffirms the case for Pfizer that <i>Barron’s</i> made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.</p><p><blockquote>新的抗病毒数据再次证实了辉瑞公司的观点：<i>巴伦</i>两年前做的。然而，随着对全球疫苗分配不平等的批评越来越多，继续从疫情中获利会带来新的风险。低收入国家在全球70多亿剂疫苗中所占比例不到1%。如果辉瑞公司抗病毒药物的分销继续有利于富裕国家，该公司的股票最终可能会受到影响。</blockquote></p><p> Pfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).</p><p><blockquote>数据公布当天，辉瑞公司股价飙升 10.9%，创下至少 20 年来最佳单日表现。尽管如此，随着该股目前在 50 美元左右易手，投资者继续低估该公司的估值。投资者对辉瑞公司的定价是明年预期收益的 12 倍，低于强生公司（JNJ）和礼来公司（LLY）等同行。</blockquote></p><p> The Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.</p><p><blockquote>辉瑞的折扣可归因于对该制药商在本世纪末面临的专利悬崖的担忧。该公司将失去少数几种每年带来数十亿美元收入的药物的独家经营权。</blockquote></p><p> The worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.</p><p><blockquote>这种担忧是合理的，但辉瑞公司的科学政变应该让投资者相信，该公司的科学能够安全地渡过悬崖。市场可能需要时间才能迎头赶上，但对于长期投资者来说，这是一个充满希望的机会。</blockquote></p><p> The success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.</p><p><blockquote>抗病毒药物的成功是辉瑞公司科学实力的最好例证。</blockquote></p><p> While Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.</p><p><blockquote>辉瑞公司的 Covid-19 疫苗来自德国生物技术公司 BioNTech (BNTX) 的实验室，而新型 Covid-19 抗病毒药物则是由多尔斯滕所说的辉瑞公司位于美国东北部的实验室科学家 “梦之队 ”研发出来的。</blockquote></p><p> In the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.</p><p><blockquote>在大流行的早期，辉瑞公司将精力分散在与 BioNTech 在疫苗方面的合作和对 Covid-19 药丸的追求上。疫苗工作规模巨大；多尔斯滕称之为横跨大西洋的 “巨型团队”。</blockquote></p><p> The antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.</p><p><blockquote>抗病毒项目是一个规模小得多的项目——一组辉瑞专家利用疫苗推广剩余的资源开展工作。</blockquote></p><p> “The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.</p><p><blockquote>“多尔斯滕说：”小分子更像是一个灵活、专注于激光的高端团队，资源相当适中。</blockquote></p><p> Dolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.</p><p><blockquote>多尔斯滕召集了辉瑞公司一些最有经验的科学家参与抗病毒项目，其中包括辉瑞公司的药物设计主管夏洛特-阿勒顿（Charlotte Allerton）。科学家们从辉瑞公司几年前在一种叫做蛋白酶抑制剂的抗病毒药物上所做的工作开始。</blockquote></p><p> “[Pfizer’s] pharmaceutical R&D is better than people had thought.”</p><p><blockquote>“辉瑞的药物研发比人们想象的要好。”</blockquote></p><p> The protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.</p><p><blockquote>然而，辉瑞文库中的蛋白酶抑制剂是静脉注射给药的，口服给药时效果不佳。该团队必须弄清楚如何使药物适应口服给药，这是一项艰巨的任务。</blockquote></p><p> “They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.</p><p><blockquote>“多尔斯滕说：”他们必须真正创造很多新的化学反应。科学家们创造了 600 种化合物来确定合适的药物，这一过程通常可能需要数年时间，但他们在几个月内就完成了。“他说：”四年在这里变成了四个月。</blockquote></p><p> Pfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).</p><p><blockquote>辉瑞公司于三月份开始在人体中测试这种药丸。目前，该公司正在对该药物进行多项 2/3 期试验，包括一项针对高危患者的试验、一项针对非高危患者的试验以及一项针对接触过病毒但尚未患病的患者的预防措施。在第一次读数中，该药物看起来比默克公司 (MRK) 的 Covid 治疗药丸更有效。</blockquote></p><p> “It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.</p><p><blockquote>“Cantor Fitzgerald 的分析师 Louise Chen 说：”这无疑有助于证明（辉瑞的）药品研发比人们想象的要好。</blockquote></p><p></p><p> Chen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.</p><p><blockquote>陈说，在 Covid-19 疫苗和药丸销售的耐久性得到更明确以及其余的管道得到证实之前，她预计投资者不会接受她的想法。</blockquote></p><p> “There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”</p><p><blockquote>“她说：”我认为没有一个事件会引发该股的评级被重新评级到下一个级别。“在这些事情发生之前，我认为不一定会发生。”</blockquote></p><p> That makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.</p><p><blockquote>这使得押注辉瑞成为一项长期战略。与此同时，Moderna (MRNA) 最近几周的经历凸显了疫苗制造商因疫苗分配不均而受到审查的可能性。</blockquote></p><p> Biden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”</p><p><blockquote>拜登政府官员对 Moderna 公司越来越不满，呼吁该公司提高产量，以便以非营利价格向低收入国家提供更多剂量，一位高级官员呼吁该公司 “加大力度”。</blockquote></p><p> Moderna shares are down more than 40% over the past three months.</p><p><blockquote>Moderna 股价在过去三个月中下跌了 40% 以上。</blockquote></p><p> As the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling <i>Barron’s</i> that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.</p><p><blockquote>随着疫情的持续，辉瑞公司可能会侵蚀大约一年前推出 Covid-19 疫苗时获得的巨大商誉。本月早些时候，辉瑞公司首席执行官布尔拉将疫苗分配不公归咎于低收入国家，并表示<i>巴伦</i>不下单是他们的错。辉瑞公司以非营利价格向美国出售了10亿剂疫苗，用于捐赠给贫困国家，并表示到明年年底将总共至少向中低收入国家交付20亿剂疫苗。</blockquote></p><p> When it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.</p><p><blockquote>当谈到抗病毒药物时，辉瑞只表示将为较贫穷的国家提供分层定价，这与它对疫苗采取的方法相同。</blockquote></p><p> That contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.</p><p><blockquote>这与默克公司向贫困国家提供自己的 Covid-19 药丸的计划形成了鲜明对比。默克公司已与一个联合国支持的组织签署了一项协议，该协议将允许其药丸在全球获得许可，而默克公司无需支付版税。</blockquote></p><p> Dolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”</p><p><blockquote>多尔斯滕说，辉瑞公司正在考虑按照与默克公司类似的机制对其药片进行许可。“他说：”我们将研究这些方案。“我们绝不是说我们会做一些不同的事情。我们只是想确保无论谁参与其中，都能获得建议和技能。”</blockquote></p><p> Such a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.</p><p><blockquote>这样的举措来得还不够快。上月底，活动人士在布尔拉家门外举行抗议活动，呼吁辉瑞公司分享其疫苗生产技术，并在富裕国家之前完成低收入国家的订单。</blockquote></p><p> An aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.</p><p><blockquote>分享其抗病毒药物的积极计划将有助于避免此类批评，使辉瑞保持相对良好的华盛顿青睐，并使其令人印象深刻的科学继续推高股价。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1\">Barrons</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.barrons.com/articles/buy-pfizer-stock-covid-19-51636674652?mod=hp_LEAD_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1102251183","content_text":"Pfizer’s chief scientific officer, Mikael Dolsten, sounded giddy when reached via telephone early Monday morning. It was just days after his company knocked the socks off the market with the news that its Covid-19 antiviral had cut the risk of hospitalization by 89% in high-risk adults.\n“It can’t be just a random thing, that you’re able to beat this type of world record and get a grand slam at the same time by chance,” Dolsten said, scrambling sports metaphors as he sought to illustrate the magnitude of Pfizer’s twin wins: the development of a stunningly effective Covid-19 vaccine in just 10 months, followed a year later by the development of a similarly stunning Covid-19 antiviral.\nTwo years ago, Pfizer (ticker: PFE) CEO Albert Bourla asked investors to take a big gamble on the research-and-development operation that Dolsten has rebuilt over the course of more than a decade. That bet is looking smarter than ever.\nBourla has gotten rid of Pfizer’s off-patent drugs division and the last of its consumer health products, leaving behind a pure-play biopharma company that will live or die on the strength of Dolsten’s science.\nIn a cover story in November 2019, Barron’s argued that Bourla and Dolsten could pull it off.\nThe new antiviral data reaffirms the case for Pfizer that Barron’s made two years ago. Continuing to profit off the pandemic, however, brings new risks, as criticism grows over the global inequity in vaccine distribution. Low-income nations account for less than 1% of the more than seven billion doses administered worldwide. If distribution of Pfizer’s antiviral continues to favor wealthy nations, the company’s stock could ultimately suffer.\nPfizer’s shares surged 10.9% the day the data came out, their best daily showing in at least 20 years. Still, with the stock now changing hands at around $50, investors continue to undervalue the company. Investors are pricing Pfizer at 12 times next year’s expected earnings, cheaper than peers like Johnson & Johnson (JNJ) and Eli Lilly (LLY).\nThe Pfizer discount can be attributed to concerns over the patent cliff the drugmaker faces at the end of the decade. The company stands to lose exclusivity over a handful of drugs that bring in billions in annual revenue.\nThe worries are legitimate, but Pfizer’s scientific coup should give investors confidence that the company’s science can carry it safely over that cliff. It may take time for the market to catch up, but for long-term investors, it’s a promising opportunity.\nThe success of the antiviral is the best illustration yet of Pfizer’s scientific prowess.\nWhile Pfizer’s Covid-19 vaccine came out of the labs of the German biotech BioNTech (BNTX), the new Covid-19 antiviral was whipped up by what Dolsten called a “dream team” of scientists at Pfizer’s own labs across the Northeast U.S.\nIn the earliest days of the pandemic, Pfizer split its efforts between its collaboration with BioNTech on the vaccine and its quest for a Covid-19 pill. The vaccine effort operated on a huge scale; Dolsten called it a “mega team” that spanned the Atlantic.\nThe antiviral project was a much smaller operation—a group of Pfizer experts operating with resources left over from the vaccine push.\n“The small molecule was more like a nimble, laser-focused, high-end team, with rather moderate resources,” Dolsten said.\nDolsten gathered some of Pfizer’s most experienced scientists to work on the antiviral project, including its head of medicine design, Charlotte Allerton. The scientists started with work Pfizer had done years ago on a type of antiviral called a protease inhibitor.\n“[Pfizer’s] pharmaceutical R&D is better than people had thought.”\nThe protease inhibitors in the Pfizer library, however, had been administered intravenously, and had not worked well when delivered orally. The team had to figure out how to adapt the drugs to oral administration, a substantial undertaking.\n“They had to really create a lot of new chemistry,” Dolsten said. The scientists created 600 compounds to nail down the right drug, a process that might normally take years, and which they accomplished in a matter of months. “Four years turned into four months here,” he said.\nPfizer started testing the pill in humans in March. It is now running a number of Phase 2/3 trials of the drug, including one for patients who are high risk, one for patients not high risk, and one as a prophylaxis for patients who have been exposed to the virus but aren’t yet sick. In the first readout, the drug looked substantially more effective than the Covid treatment pill from Merck (MRK).\n“It definitely helps prove the point that [Pfizer’s] pharmaceutical R&D is better than people had thought,” says Louise Chen, an analyst at Cantor Fitzgerald, who has an Overweight rating and a $61 price target on the stock.\nChen says that she doesn’t expect investors to come around to her way of thinking until there is more clarity on the durability of Covid-19 vaccine and pill sales, and the rest of the pipeline gets proved out.\n“There is not one event that I think will trigger a re-rating of the stock at the next level,” she says. “Until those things play out, I don’t think that it necessarily will.”\nThat makes a bet on Pfizer a long-term play. In the meantime, the experience of Moderna (MRNA) in recent weeks is highlighting the potential for the vaccine makers to come under scrutiny over unequal distribution of vaccines.\nBiden administration officials have been increasingly frustrated with Moderna, calling on the company to ramp up production so it can offer more doses at not-for-profit prices to low-income countries, with one top official calling on the company to “step up.”\nModerna shares are down more than 40% over the past three months.\nAs the pandemic persists, Pfizer risks eroding the enormous goodwill it earned roughly a year ago when it introduced its Covid-19 vaccine. Earlier this month, Pfizer CEO Bourla blamed low-income countries for unfair vaccine distribution, telling Barron’s that it was their fault for not placing orders. Pfizer has sold a billion vaccine doses to the U.S. at a not-for-profit price to donate to poor countries, and says that a total of at least two billion doses will be delivered to low- and middle-income nations by the end of next year.\nWhen it comes to antivirals, Pfizer has said only that it will offer tiered pricing for poorer nations, the same approach it has taken with its vaccine.\nThat contrasts sharply with Merck’s plan to make its own Covid-19 pill available to poor countries. Merck has signed a deal with a United Nations-backed group that will allow its pill to be licensed globally, with no royalties paid to Merck.\nDolsten said that Pfizer is looking into licensing its pill under a similar mechanism as Merck’s. “We will look at those options,” he said. “By no means have we said we would do something different. We just want to make sure whoever will be involved gets the advice and skill to do this.”\nSuch a step couldn’t come soon enough. Late last month, activists protested outside Bourla’s home, calling on Pfizer to share its vaccine manufacturing technology and to fill orders from low-income countries ahead of those from wealthy countries.\nAn aggressive plan to share its antiviral would help stave off such criticism, keeping Pfizer in the relative good graces of Washington and allowing its impressive science to continue to drive the stock higher.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":2884,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":847285132,"gmtCreate":1636524401929,"gmtModify":1636524758936,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847285132","repostId":"1188205095","repostType":4,"isVote":1,"tweetType":1,"viewCount":2965,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":868517299,"gmtCreate":1632671469211,"gmtModify":1632798663240,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"ss","listText":"ss","text":"ss","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/868517299","repostId":"1142057327","repostType":4,"repost":{"id":"1142057327","kind":"news","pubTimestamp":1632643246,"share":"https://www.laohunote.com/m/news/1142057327?lang=zh_CN&edition=full","pubTime":"2021-09-26 16:00","market":"us","language":"en","title":"Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始在亚利桑那州建设两家计算机芯片工厂</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1142057327","media":"The street","summary":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to","content":"<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.</p><p><blockquote>英特尔在亚利桑那州破土动工了两家新的计算机芯片工厂，这是一项耗资 200 亿美元的项目的一部分，旨在帮助满足美国对半导体的高需求。</blockquote></p><p> Intel (<b>INTC</b>) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.</p><p><blockquote>英特尔（<b>国际电联</b>) -Get 英特尔公司 (INTC) 周五报道称，英特尔公司 (INTC) 在亚利桑那州的两家新计算机芯片工厂破土动工，这是一项耗资 200 亿美元的项目的一部分，旨在帮助缓解美国半导体严重短缺的问题。</blockquote></p><p> The Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.</p><p><blockquote>这家总部位于加利福尼亚州圣克拉拉的半导体芯片制造商的首席执行官帕特·基辛格在该公司位于亚利桑那州钱德勒的奥科蒂略园区主持了该项目的奠基仪式，这标志着该州历史上最大的私人投资。</blockquote></p><p> Intel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.</p><p><blockquote>英特尔预计这些工厂将于 2024 年全面投入运营，生产公司最先进的工艺技术。</blockquote></p><p> “Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.</p><p><blockquote>“基辛格在公司声明中说：”今天的庆祝活动标志着一个重要的里程碑，因为我们正在努力提高产能，满足对半导体的巨大需求： 半导体是一切数字化的基础技术。“我们正在迎来一个创新的新时代--对英特尔、对亚利桑那州乃至对全世界来说都是如此。自 40 多年前开设工厂以来，我们在亚利桑那州的总投资将超过 500 亿美元。</blockquote></p><p> \"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.</p><p><blockquote>“作为唯一一家总部位于美国的领先芯片制造商，我们致力于在这项长期投资的基础上再接再厉，帮助美国重新获得半导体领域的领导地位，”基辛格说。</blockquote></p><p> Shares of Intel on Friday traded 0.18% higher to $54.32 after hours.</p><p><blockquote>英特尔股价周五盘后上涨 0.18%，至 54.32 美元。</blockquote></p><p> Gelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.</p><p><blockquote>基辛格周四参加了与科技公司高管和商务部长吉娜·雷蒙多的虚拟会议，以解决全球半导体芯片短缺问题，这干扰了高科技、电子和汽车行业的生产。</blockquote></p><p> The two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.</p><p><blockquote>这两家新工厂将被命名为 Fab 52 和 Fab 62，总共将容纳六家半导体晶圆厂。该项目将创造3000多个高科技、高工资的英特尔工作岗位、3000个建筑工作岗位，并在当地社区支持约15000个额外的间接工作岗位。</blockquote></p><p> Intel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.</p><p><blockquote>英特尔竞争对手台积电公司计划在亚利桑那州建造第二家美国芯片工厂，并计划于 2024 年开始生产。</blockquote></p><p></p>","source":"lsy1610613172068","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始在亚利桑那州建设两家计算机芯片工厂</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntel Starts Construction of Two Arizona Computer Chip Factories<blockquote>英特尔开始在亚利桑那州建设两家计算机芯片工厂</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">The street</strong><span class=\"h-time small\">2021-09-26 16:00</span>\n</p>\n</h4>\n</header>\n<article>\n<p>Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.</p><p><blockquote>英特尔在亚利桑那州破土动工了两家新的计算机芯片工厂，这是一项耗资 200 亿美元的项目的一部分，旨在帮助满足美国对半导体的高需求。</blockquote></p><p> Intel (<b>INTC</b>) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.</p><p><blockquote>英特尔（<b>国际电联</b>) -Get 英特尔公司 (INTC) 周五报道称，英特尔公司 (INTC) 在亚利桑那州的两家新计算机芯片工厂破土动工，这是一项耗资 200 亿美元的项目的一部分，旨在帮助缓解美国半导体严重短缺的问题。</blockquote></p><p> The Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.</p><p><blockquote>这家总部位于加利福尼亚州圣克拉拉的半导体芯片制造商的首席执行官帕特·基辛格在该公司位于亚利桑那州钱德勒的奥科蒂略园区主持了该项目的奠基仪式，这标志着该州历史上最大的私人投资。</blockquote></p><p> Intel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.</p><p><blockquote>英特尔预计这些工厂将于 2024 年全面投入运营，生产公司最先进的工艺技术。</blockquote></p><p> “Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.</p><p><blockquote>“基辛格在公司声明中说：”今天的庆祝活动标志着一个重要的里程碑，因为我们正在努力提高产能，满足对半导体的巨大需求： 半导体是一切数字化的基础技术。“我们正在迎来一个创新的新时代--对英特尔、对亚利桑那州乃至对全世界来说都是如此。自 40 多年前开设工厂以来，我们在亚利桑那州的总投资将超过 500 亿美元。</blockquote></p><p> \"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.</p><p><blockquote>“作为唯一一家总部位于美国的领先芯片制造商，我们致力于在这项长期投资的基础上再接再厉，帮助美国重新获得半导体领域的领导地位，”基辛格说。</blockquote></p><p> Shares of Intel on Friday traded 0.18% higher to $54.32 after hours.</p><p><blockquote>英特尔股价周五盘后上涨 0.18%，至 54.32 美元。</blockquote></p><p> Gelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.</p><p><blockquote>基辛格周四参加了与科技公司高管和商务部长吉娜·雷蒙多的虚拟会议，以解决全球半导体芯片短缺问题，这干扰了高科技、电子和汽车行业的生产。</blockquote></p><p> The two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.</p><p><blockquote>这两家新工厂将被命名为 Fab 52 和 Fab 62，总共将容纳六家半导体晶圆厂。该项目将创造3000多个高科技、高工资的英特尔工作岗位、3000个建筑工作岗位，并在当地社区支持约15000个额外的间接工作岗位。</blockquote></p><p> Intel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.</p><p><blockquote>英特尔竞争对手台积电公司计划在亚利桑那州建造第二家美国芯片工厂，并计划于 2024 年开始生产。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories\">The street</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"INTC":"英特尔"},"source_url":"https://www.thestreet.com/investing/intel-starts-construction-of-two-arizona-computer-chip-factories","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142057327","content_text":"Intel broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help meet the high demand for semiconductors in the U.S.\nIntel (INTC) -Get Intel Corporation (INTC) Report on Friday broke ground on two new computer chip factories in Arizona as part of a $20 billion project to help alleviate the severe shortage of semiconductors in the U.S.\nThe Santa Clara, Calif.-basedsemiconductor chip manufacturer'sCEO Pat Gelsinger led the project's groundbreaking ceremony at the company's Ocotillo campus in Chandler, Ariz., marking the largest private investment in the state's history.\nIntel expects the factories to be fully operational in 2024 to manufacture the company's most advanced process technologies.\n“Today’s celebration marks an important milestone as we work to boost capacity and meet the incredible demand for semiconductors: the foundational technology for the digitization of everything,\" Gelsinger said in acompany statement. \"We are ushering in a new era of innovation – for Intel, for Arizona and for the world. This $20 billion expansion will bring our total investment in Arizona to more than $50 billion since opening the site over 40 years ago.\n\"As the only U.S.-based leading-edge chipmaker, we are committed to building on this long-term investment and helping the United States regain semiconductor leadership,” Gelsinger said.\nShares of Intel on Friday traded 0.18% higher to $54.32 after hours.\nGelsinger on Thursday participated in a virtual meeting with tech company executives and Commerce Secretary Gina Raimondo to address the global semiconductor chip shortage, which has interfered with production in the high-tech, electronics and automotive industries.\nThe two new factories, to be named Fab 52 and Fab 62, will house a total of six semiconductor fabs. The project will create over 3,000 high-tech, high-wage Intel jobs, 3,000 construction jobs and support an estimated 15,000 additional indirect jobs in the local community.\nIntel rival Taiwan Semiconductor Manufacturing Co.plans to buildits second U.S. chip factory also in Arizona and targets production to begin in 2024.","news_type":1,"symbols_score_info":{"INTC":0.9}},"isVote":1,"tweetType":1,"viewCount":2230,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":861838061,"gmtCreate":1632479579653,"gmtModify":1632719680697,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"s","listText":"s","text":"s","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861838061","repostId":"1147407851","repostType":4,"repost":{"id":"1147407851","kind":"news","pubTimestamp":1632476902,"share":"https://www.laohunote.com/m/news/1147407851?lang=zh_CN&edition=full","pubTime":"2021-09-24 17:48","market":"us","language":"en","title":"EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据，欧盟将等待决定辉瑞加强剂</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1147407851","media":"zerohedge","summary":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing","content":"<p>In keeping with their more cautious approach toward approving COVID jabs,<b>EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jab</b>s - but not until early October,Reuters reportedThursday.</p><p><blockquote>为了与他们在批准新冠疫苗接种方面更加谨慎的态度保持一致，<b>欧盟监管机构正准备自行决定是否批准辉瑞疫苗加强注射</b>路透社周四报道称，但要到 10 月初。</blockquote></p><p> Reuters pointed out that<b>the upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabs</b>in the EU.</p><p><blockquote>路透社指出，<b>即将对辉瑞加强针进行的审查将标志着欧洲监管机构首次决定发放加强针</b>在欧盟。</blockquote></p><p> In an opinion issued earlier this month that was republished by the EMA,<b>the European Center for Disease Prevention and Control</b>- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -<b>said there was no \"urgent need\" to administer booster doses</b>to fully vaccinated individuals in the general population.</p><p><blockquote>在本月早些时候发布并由 EMA 重新发布的一份意见中，<b>欧洲疾病预防控制中心</b>-或ECDC，由欧盟最高级别卫生监管机构组成的几个监管机构之一-<b>表示没有“迫切需要”注射加强剂量</b>普通人群中完全接种疫苗的个体。</blockquote></p><p> But it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever</p><p><blockquote>但它也指出，已经在考虑额外的剂量，并分发给老年人、免疫力低下的人和其他什么人</blockquote></p><p> Regardless of whatever the bloc decides,<b>it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.</b></p><p><blockquote>不管集团做出什么决定，<b>该公司最近已经与辉瑞和 BioNTech 签署了额外 24 亿次 mRNA 注射的协议。</b></blockquote></p><p> The latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.</p><p><blockquote>最新合同包括供应至少900毫米口径的子弹，只有在欧盟继续实施广泛的加强注射计划并向所有16岁及以上的成年人提供这些子弹的情况下才需要。超过70%的欧盟成年人口已经完全接种了疫苗，欧盟已经从几家制造商那里获得了充足的疫苗供应。</blockquote></p><p> Still, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.</p><p><blockquote>尽管如此，随着三角洲浪潮继续给世界各地的政治家带来问题，他们可能会越来越不顾一切地迫使人们接种3次、4次甚至5次疫苗——尽管ECDC表示，关于加强剂的必要性和安全性的关键数据尚未从世界各地开展的研究中收集到rfhr n，部分原因是目前还不完全清楚疫苗对病毒的保护时间有多长。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据，欧盟将等待决定辉瑞加强剂</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU Will Wait To Decide On Pfizer Boosters Due To Shortage Of Safety Data<blockquote>由于缺乏安全数据，欧盟将等待决定辉瑞加强剂</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">zerohedge</strong><span class=\"h-time small\">2021-09-24 17:48</span>\n</p>\n</h4>\n</header>\n<article>\n<p>In keeping with their more cautious approach toward approving COVID jabs,<b>EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jab</b>s - but not until early October,Reuters reportedThursday.</p><p><blockquote>为了与他们在批准新冠疫苗接种方面更加谨慎的态度保持一致，<b>欧盟监管机构正准备自行决定是否批准辉瑞疫苗加强注射</b>路透社周四报道称，但要到 10 月初。</blockquote></p><p> Reuters pointed out that<b>the upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabs</b>in the EU.</p><p><blockquote>路透社指出，<b>即将对辉瑞加强针进行的审查将标志着欧洲监管机构首次决定发放加强针</b>在欧盟。</blockquote></p><p> In an opinion issued earlier this month that was republished by the EMA,<b>the European Center for Disease Prevention and Control</b>- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -<b>said there was no \"urgent need\" to administer booster doses</b>to fully vaccinated individuals in the general population.</p><p><blockquote>在本月早些时候发布并由 EMA 重新发布的一份意见中，<b>欧洲疾病预防控制中心</b>-或ECDC，由欧盟最高级别卫生监管机构组成的几个监管机构之一-<b>表示没有“迫切需要”注射加强剂量</b>普通人群中完全接种疫苗的个体。</blockquote></p><p> But it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever</p><p><blockquote>但它也指出，已经在考虑额外的剂量，并分发给老年人、免疫力低下的人和其他什么人</blockquote></p><p> Regardless of whatever the bloc decides,<b>it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.</b></p><p><blockquote>不管集团做出什么决定，<b>该公司最近已经与辉瑞和 BioNTech 签署了额外 24 亿次 mRNA 注射的协议。</b></blockquote></p><p> The latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.</p><p><blockquote>最新合同包括供应至少900毫米口径的子弹，只有在欧盟继续实施广泛的加强注射计划并向所有16岁及以上的成年人提供这些子弹的情况下才需要。超过70%的欧盟成年人口已经完全接种了疫苗，欧盟已经从几家制造商那里获得了充足的疫苗供应。</blockquote></p><p> Still, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.</p><p><blockquote>尽管如此，随着三角洲浪潮继续给世界各地的政治家带来问题，他们可能会越来越不顾一切地迫使人们接种3次、4次甚至5次疫苗——尽管ECDC表示，关于加强剂的必要性和安全性的关键数据尚未从世界各地开展的研究中收集到rfhr n，部分原因是目前还不完全清楚疫苗对病毒的保护时间有多长。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29\">zerohedge</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞"},"source_url":"https://www.zerohedge.com/geopolitical/eu-will-wait-decide-pfizer-boosters-due-shortage-safety-data?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+zerohedge%2Ffeed+%28zero+hedge+-+on+a+long+enough+timeline%2C+the+survival+rate+for+everyone+drops+to+zero%29","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1147407851","content_text":"In keeping with their more cautious approach toward approving COVID jabs,EU regulators are preparing to make their own decisions about whether to approve booster shots with Pfizer jabs - but not until early October,Reuters reportedThursday.\nReuters pointed out thatthe upcoming review of the Pfizer booster jab would mark the European regulators' first decision about doling out booster jabsin the EU.\nIn an opinion issued earlier this month that was republished by the EMA,the European Center for Disease Prevention and Control- or ECDC, one of several regulators that comprises the EU's highest-level of health regulators -said there was no \"urgent need\" to administer booster dosesto fully vaccinated individuals in the general population.\nBut it also noted that additional doses are already being considered and doled out to the elderly, the immuno-compromised, and whatever\nRegardless of whatever the bloc decides,it has already signed recent deals with Pfizer and BioNTech for 2.4 billion more mRNA jabs.\nThe latest contract covers the supply of at least 900MM shots, which will only be needed if the EU goes ahead with expansive booster jab program and offers them to all adults 16 and up. . Over 70% of the EU's adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.\nStill, as the delta wave continues to create problems for politicians around the world, they might grow increasingly desperate to force the population to get 3, 4 or even 5 jabs - despite the fact that The ECDC has said crucial data on the need and safety of boosters hasn't yet been gleaned from the studies unfurling around the world rfhr n in part because it is not yet fully clear how long vaccines protect against the virus.","news_type":1,"symbols_score_info":{"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":4688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":860763767,"gmtCreate":1632214972359,"gmtModify":1632802025039,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"h","listText":"h","text":"h","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/860763767","repostId":"1138597781","repostType":4,"repost":{"id":"1138597781","kind":"news","pubTimestamp":1632214755,"share":"https://www.laohunote.com/m/news/1138597781?lang=zh_CN&edition=full","pubTime":"2021-09-21 16:59","market":"us","language":"en","title":"Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>全球股市反弹，道琼斯、纳斯达克、标普500期货上涨</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138597781","media":"seekingalpha","summary":"The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again t","content":"<p>The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.</p><p><blockquote>昨天在华尔街交易最后一个小时介入的逢低买家今天又回来了，推动全球股市走高。</blockquote></p><p> S&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.</p><p><blockquote>标准普尔期货 (SPX)、纳斯达克 100 期货 (NDX:IND) 和道琼斯期货 (INDU) 均上涨约 1%。</blockquote></p><p> In Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.</p><p><blockquote>在亚洲，日本日经指数（NKY:IND）走低，赶上了周一假期后的交易，但香港恒生指数（HSI）上涨了0.5%以上。</blockquote></p><p> In Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.</p><p><blockquote>在欧洲，法兰克福、伦敦和巴黎的基准指数上涨超过 1%，其中斯托克 600 指数 (STOXX) 上涨 1%。</blockquote></p><p> Rates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.</p><p><blockquote>利率正在减少损失，10 年期国债收益率 (NYSEARCA:TBT)(NASDAQ:TLT) 上涨 3 个基点至 1.34%。</blockquote></p><p> And volatility is ebbing. The S&P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.</p><p><blockquote>波动性正在减弱。标准普尔 VIX 指数 (VIX)（也称为恐惧指标）在昨天飙升后下跌 12%。</blockquote></p><p> The VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.</p><p><blockquote>VIX “自 5 月份以来首次突破 25，这一上涨可能加剧了部分下跌，风险模型迫使随着波动性上升而削减头寸，从而增加抛售，加剧了波动性的进一步增加；等等，”卡克斯顿高级市场分析师迈克尔·布朗 (Michael Brown) 写道。</blockquote></p><p> <b>No Lehman moment.</b>Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.</p><p><blockquote><b>没有雷曼时刻。</b>对中国恒大违约对利息支付的影响的担忧一夜之间有所缓解。</blockquote></p><p> S&P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.</p><p><blockquote>标准普尔全球评级表示，除非恒大存在系统性风险和“深远”的传染，否则政府救助的可能性不大。</blockquote></p><p> But the S&P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"</p><p><blockquote>但标准普尔分析师也表示，这家房地产公司“单独失败不太可能导致这种情况”。</blockquote></p><p> \"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.</p><p><blockquote>德意志银行（Deutsche Bank）策略师吉姆-里德（Jim Reid）今天写道：“恒大和中国房地产行业的危机是大多数人谈论的（抛售）催化剂，但说实话，我们看到的市场溃败反映的风险不仅仅是中国房地产，而且在越来越多的人质疑当前的估值是否仍然合理之后，关于潜在调整的讨论也越来越多。”</blockquote></p><p> \"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.</p><p><blockquote>“请记住，在我上周的调查中，68% 的受访者认为年底前股市至少会出现 5% 的调整。因此，即使催化剂尚不明确，这也一直是人们关注的焦点，”他补充道。</blockquote></p><p> <b>Time to buy?</b>Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.</p><p><blockquote><b>是时候买了吗？</b>周一的暴跌带来了华尔街银行的一些看涨评级，一些策略师仍然看到大盘向上和向右移动的路径。</blockquote></p><p> \"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”</p><p><blockquote>“摩根大通首席全球市场策略师马尔科-科拉诺维奇（Marko Kolanovic）昨天在一份报告中写道：”我们认为，一夜之间升级的市场抛售主要是由流动性差环境下的技术性抛售流（CTA 和期权对冲）以及全权交易者对感知风险的过度反应所驱动的。“我们的基本论点保持不变，我们将此次抛售视为逢低买入的机会。”</blockquote></p><p> From a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"</p><p><blockquote>从技术角度来看，Piper Sandler 策略师克雷格·W·约翰逊 (Craig W. Johnson) 称本周是“逢低买入人群的关键考验”，未能捍卫标准普尔 4,436 点左右的 50 日移动平均线“将表明大盘面临更深层次回调的风险。”</blockquote></p><p> But Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.</p><p><blockquote>但 Fundstrat 研究主管托马斯·李 (Thomas Lee) 同意科拉诺维奇的观点，他在 CNBC 上表示，现在是考虑增加头寸的时候了。</blockquote></p><p> \"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.</p><p><blockquote>李说：“我认为像这样的抛售（这是一种广泛的抛售）是逐步增加的时候。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>全球股市反弹，道琼斯、纳斯达克、标普500期货上涨</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDow Jones, Nasdaq, S&P 500 futures rally as global equities bounce back<blockquote>全球股市反弹，道琼斯、纳斯达克、标普500期货上涨</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">seekingalpha</strong><span class=\"h-time small\">2021-09-21 16:59</span>\n</p>\n</h4>\n</header>\n<article>\n<p>The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.</p><p><blockquote>昨天在华尔街交易最后一个小时介入的逢低买家今天又回来了，推动全球股市走高。</blockquote></p><p> S&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.</p><p><blockquote>标准普尔期货 (SPX)、纳斯达克 100 期货 (NDX:IND) 和道琼斯期货 (INDU) 均上涨约 1%。</blockquote></p><p> In Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.</p><p><blockquote>在亚洲，日本日经指数（NKY:IND）走低，赶上了周一假期后的交易，但香港恒生指数（HSI）上涨了0.5%以上。</blockquote></p><p> In Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.</p><p><blockquote>在欧洲，法兰克福、伦敦和巴黎的基准指数上涨超过 1%，其中斯托克 600 指数 (STOXX) 上涨 1%。</blockquote></p><p> Rates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.</p><p><blockquote>利率正在减少损失，10 年期国债收益率 (NYSEARCA:TBT)(NASDAQ:TLT) 上涨 3 个基点至 1.34%。</blockquote></p><p> And volatility is ebbing. The S&P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.</p><p><blockquote>波动性正在减弱。标准普尔 VIX 指数 (VIX)（也称为恐惧指标）在昨天飙升后下跌 12%。</blockquote></p><p> The VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.</p><p><blockquote>VIX “自 5 月份以来首次突破 25，这一上涨可能加剧了部分下跌，风险模型迫使随着波动性上升而削减头寸，从而增加抛售，加剧了波动性的进一步增加；等等，”卡克斯顿高级市场分析师迈克尔·布朗 (Michael Brown) 写道。</blockquote></p><p> <b>No Lehman moment.</b>Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.</p><p><blockquote><b>没有雷曼时刻。</b>对中国恒大违约对利息支付的影响的担忧一夜之间有所缓解。</blockquote></p><p> S&P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.</p><p><blockquote>标准普尔全球评级表示，除非恒大存在系统性风险和“深远”的传染，否则政府救助的可能性不大。</blockquote></p><p> But the S&P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"</p><p><blockquote>但标准普尔分析师也表示，这家房地产公司“单独失败不太可能导致这种情况”。</blockquote></p><p> \"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.</p><p><blockquote>德意志银行（Deutsche Bank）策略师吉姆-里德（Jim Reid）今天写道：“恒大和中国房地产行业的危机是大多数人谈论的（抛售）催化剂，但说实话，我们看到的市场溃败反映的风险不仅仅是中国房地产，而且在越来越多的人质疑当前的估值是否仍然合理之后，关于潜在调整的讨论也越来越多。”</blockquote></p><p> \"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.</p><p><blockquote>“请记住，在我上周的调查中，68% 的受访者认为年底前股市至少会出现 5% 的调整。因此，即使催化剂尚不明确，这也一直是人们关注的焦点，”他补充道。</blockquote></p><p> <b>Time to buy?</b>Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.</p><p><blockquote><b>是时候买了吗？</b>周一的暴跌带来了华尔街银行的一些看涨评级，一些策略师仍然看到大盘向上和向右移动的路径。</blockquote></p><p> \"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”</p><p><blockquote>“摩根大通首席全球市场策略师马尔科-科拉诺维奇（Marko Kolanovic）昨天在一份报告中写道：”我们认为，一夜之间升级的市场抛售主要是由流动性差环境下的技术性抛售流（CTA 和期权对冲）以及全权交易者对感知风险的过度反应所驱动的。“我们的基本论点保持不变，我们将此次抛售视为逢低买入的机会。”</blockquote></p><p> From a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"</p><p><blockquote>从技术角度来看，Piper Sandler 策略师克雷格·W·约翰逊 (Craig W. Johnson) 称本周是“逢低买入人群的关键考验”，未能捍卫标准普尔 4,436 点左右的 50 日移动平均线“将表明大盘面临更深层次回调的风险。”</blockquote></p><p> But Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.</p><p><blockquote>但 Fundstrat 研究主管托马斯·李 (Thomas Lee) 同意科拉诺维奇的观点，他在 CNBC 上表示，现在是考虑增加头寸的时候了。</blockquote></p><p> \"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.</p><p><blockquote>李说：“我认为像这样的抛售（这是一种广泛的抛售）是逐步增加的时候。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://seekingalpha.com/news/3741654-dow-jones-nasdaq-sp-500-futures-rally-as-global-equities-bounce-back\">seekingalpha</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index","SPY":"标普500ETF",".DJI":"道琼斯"},"source_url":"https://seekingalpha.com/news/3741654-dow-jones-nasdaq-sp-500-futures-rally-as-global-equities-bounce-back","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138597781","content_text":"The dip-buyers who stepped in during the last hour of Wall Street trading yesterday are back again today, pushing stocks higher around the world.\nS&P futures(SPX), Nasdaq 100 futures(NDX:IND)and Dow Jones futures(INDU)are all up about 1%.\nIn Asia, Japan's Nikkei(NKY:IND)is lower, catching up with trading after a holiday on Monday, but Hong Kong's Hang Seng(HSI)is up more than half a percent.\nIn Europe, the benchmark indexes in Frankfurt, London and Paris are more than 1% higher, with the broader Stoxx 600(STOXX)up 1%.\nRates are paring losses, with the 10-year Treasury yield(NYSEARCA:TBT)(NASDAQ:TLT)up 3 basis points to 1.34%.\nAnd volatility is ebbing. The S&P Vix Index(VIX), also referred to as the fear gauge, is down 12% after a surge yesterday.\nThe VIX \"traded north of 25 for the first time since May, a rise which is likely to have exacerbated some of the declines, with risk models forcing positions to be trimmed as volatility climbs, thus increasing selling, fueling a further increase in volatility; and so on, and so forth,\" Michael Brown, senior market analyst at Caxton writes.\nNo Lehman moment.Jitters about the impact of China's Evergrande defaulting on interest payments have eased overnight.\nS&P Global Ratings says that a governmentbailout is unlikely unless there is systemic risk and \"far-reaching\" contagion from Evergrande.\nBut the S&P analysts also say the property company \"failing alone would unlikely result in such a scenario.\"\n\"The crisis at Evergrande and in the Chinese real estate sector was the catalyst (for a selloff) most people were talking about, but truth be told, the market rout we’re seeing is reflecting a wider set of risks than just Chinese property, and comes after increasing questions have been asked about whether current valuations could still be justified, with talk of a potential correction picking up,\" Deutsche Bank strategist Jim Reid writes today.\n\"Remember that 68% of respondents to my survey last week thought they’d be at least a 5% correction in equity markets before year end. So this has been front and center of people’s mind even if the catalyst hasn’t been clear,\" he adds.\nTime to buy?Monday's tumble brought some bullish calls from Wall Street banks, where several strategists still see the path of the broader market moving up and to the right.\n\"The market sell-off that escalated overnight we believe is primarily driven by technical selling flows (CTAs and option hedgers) in an environment of poor liquidity, and overreaction of discretionary traders to perceived risks,” Marko Kolanovic, chief global market strategist at JPMorgan, wrote in a note yesterday. “Our fundamental thesis remains unchanged, and we see the sell-off as an opportunity to buy the dip.”\nFrom a technical perspective, Piper Sandler strategist Craig W. Johnson called this week a \"key test for the buy the dip crowd\" and that a failure to defend the S&P's 50-day moving average around 4,436 \"would suggest the broader market is at risk for a deeper pullback.\"\nBut Thomas Lee, head of research at Fundstrat, agreed with Kolanovic, saying on CNBC the time was right to look at adding to positions.\n\"I would look at selloffs like this, which is sort of broad-based selling, as a time to add incrementally,\"Lee said.","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,"SPY":0.9,".SPX":0.9}},"isVote":1,"tweetType":1,"viewCount":2167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":860850406,"gmtCreate":1632154329105,"gmtModify":1632802448027,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"d","listText":"d","text":"d","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/860850406","repostId":"2168268325","repostType":4,"isVote":1,"tweetType":1,"viewCount":3855,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":885654617,"gmtCreate":1631790309739,"gmtModify":1631889585555,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"b","listText":"b","text":"b","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885654617","repostId":"1133643403","repostType":4,"isVote":1,"tweetType":1,"viewCount":3515,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":886974284,"gmtCreate":1631547272448,"gmtModify":1631889585568,"author":{"id":"3585997214465926","authorId":"3585997214465926","name":"fann","avatar":"https://static.tigerbbs.com/c31475daaad7003b58f3385789c2f471","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3585997214465926","idStr":"3585997214465926"},"themes":[],"title":"","htmlText":"f","listText":"f","text":"f","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/886974284","repostId":"2166303094","repostType":4,"isVote":1,"tweetType":1,"viewCount":3579,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}